NovoCure (NVCR) Aktienübersicht
NovoCure Limited, ein Onkologieunternehmen, beschäftigt sich mit der Entwicklung, Herstellung und Vermarktung von Geräten zur Behandlung von Tumorfeldern (TTFields) für die Behandlung von soliden Tumoren in den Vereinigten Staaten, Deutschland, Frankreich, Japan, Greater China und international. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 4/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 0/6 |
NVCR Community Fair Values
Create NarrativeSee what 26 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
NovoCure Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$18.26 |
| 52-Wochen-Hoch | US$20.06 |
| 52-Wochen-Tief | US$9.82 |
| Beta | 0.90 |
| 1 Monat Veränderung | 46.43% |
| 3 Monate Veränderung | 21.81% |
| 1 Jahr Veränderung | -4.80% |
| 3 Jahre Veränderung | -74.30% |
| 5 Jahre Veränderung | -90.99% |
| Veränderung seit IPO | -0.11% |
Aktuelle Nachrichten und Updates
Narrativ-Update • May 17
NVCR: Mixed TTFields Progress And Guidance Will Shape Shares In 2026
NovoCure's analyst price target has increased from $13.50 to $17.00, with analysts citing updated assumptions around revenue growth, discount rates, profit margins, and future P/E multiples as key drivers of the change. Analyst Commentary Recent Street research shows that views on NovoCure remain mixed, with some analysts lifting price targets and others trimming them as they revisit assumptions around revenue growth, discount rates, profit margins, and future P/E multiples.Narrativ-Update • May 02
NVCR: Execution Risks Around TTFields Pancreatic Cancer Rollout Will Pressure Shares
Analysts now see NovoCure's fair value holding around $13.50 per share, with the latest price target revisions reflecting updated views on revenue growth, profit margins, and a modestly higher future P/E assumption, based on recent Street research that included both price target increases and reductions. Analyst Commentary Recent Street research around NovoCure shows a split view on the stock, with some firms adjusting price targets in different directions.Seeking Alpha • May 01
NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet
Summary NovoCure Limited has resolved its CMS billing issue, with no material impact on operations or financials. Q1 2026 revenues grew 12% year-over-year to $174.1M; gross margins improved to 78%, and full-year guidance was raised to $690–710M. Optune Pax launch shows promising demand, but sustainability remains uncertain; Optune Lua for lung cancer has disappointed. I maintain a Hold rating, awaiting clear evidence of sustained cash generation and robust new growth drivers, especially from pancreatic cancer and TRIDENT trial results. Read the full article on Seeking AlphaRecent updates
Narrativ-Update • May 17
NVCR: Mixed TTFields Progress And Guidance Will Shape Shares In 2026
NovoCure's analyst price target has increased from $13.50 to $17.00, with analysts citing updated assumptions around revenue growth, discount rates, profit margins, and future P/E multiples as key drivers of the change. Analyst Commentary Recent Street research shows that views on NovoCure remain mixed, with some analysts lifting price targets and others trimming them as they revisit assumptions around revenue growth, discount rates, profit margins, and future P/E multiples.Narrativ-Update • May 02
NVCR: Execution Risks Around TTFields Pancreatic Cancer Rollout Will Pressure Shares
Analysts now see NovoCure's fair value holding around $13.50 per share, with the latest price target revisions reflecting updated views on revenue growth, profit margins, and a modestly higher future P/E assumption, based on recent Street research that included both price target increases and reductions. Analyst Commentary Recent Street research around NovoCure shows a split view on the stock, with some firms adjusting price targets in different directions.Seeking Alpha • May 01
NovoCure: Pancreatic Launch Looks Promising, But I'm Not A Believer Yet
Summary NovoCure Limited has resolved its CMS billing issue, with no material impact on operations or financials. Q1 2026 revenues grew 12% year-over-year to $174.1M; gross margins improved to 78%, and full-year guidance was raised to $690–710M. Optune Pax launch shows promising demand, but sustainability remains uncertain; Optune Lua for lung cancer has disappointed. I maintain a Hold rating, awaiting clear evidence of sustained cash generation and robust new growth drivers, especially from pancreatic cancer and TRIDENT trial results. Read the full article on Seeking AlphaNarrativ-Update • Apr 17
NVCR: Mixed Research Views And Trial Progress Will Shape Future Risk Balance
Analysts have trimmed their average price target for NovoCure by $1.00 to $13.50, citing updated assumptions for fair value, discount rate, revenue, profit margin and future P/E following recent mixed target revisions from the Street. Analyst Commentary Recent Street research presents a mixed picture for NovoCure, with one target cut and another raised in close succession.
Narrativ-Update • Apr 03
NVCR: Recovering Procedure Trends And 2026 Tools Play Will Drive Upside
NovoCure Narrative Update The updated analyst price target for NovoCure reflects a modest upward move to $26.07. This is supported by mixed recent Street research, where some analysts highlight recovering end markets, healthier procedure and CapEx trends into 2026, and early recovery signs in China.
Narrativ-Update • Mar 19
NVCR: Recovering Medtech Demand Will Support 2026 Tools Upside Potential
Narrative Update: NovoCure Price Target Reset Analysts have lifted their NovoCure price target by $5.38, citing updated assumptions that include a lower discount rate, higher modeled revenue growth and profit margin, and a slightly reduced future P/E multiple. Analyst Commentary Bullish analysts see the recent price target moves as part of a constructive re-rating story for NovoCure, with expectations focused on execution of growth initiatives and clearer earnings visibility over the medium term.Narrativ-Update • Mar 05
NVCR: Recovering Procedure Trends And 2026 Tools Setup Will Drive Upside
NovoCure’s updated analyst price target has moved modestly higher to about $26, as analysts factor in a slightly lower discount rate and different assumptions around long term growth, margins and future P/E multiples. Analyst Commentary Recent research on NovoCure highlights a mix of optimism around longer term growth optionality and caution around external policy risks and market rotations that could affect how quickly that potential is reflected in the share price.Narrativ-Update • Feb 19
NVCR: Recovering Procedure Trends And 2026 Tools Setup Will Support Upside
Analysts have modestly lifted their fair value estimate for NovoCure to $25.21 from $24.07. This reflects updated views on revenue growth, profit margins, discount rates, and P/E assumptions following recent mixed price target changes on the Street.Analyseartikel • Feb 12
NovoCure Limited's (NASDAQ:NVCR) 26% Dip In Price Shows Sentiment Is Matching Revenues
NovoCure Limited ( NASDAQ:NVCR ) shareholders won't be pleased to see that the share price has had a very rough month...Narrativ-Update • Feb 05
NVCR: Recovering Procedure Trends And 2026 Tools Setup Will Support Shares
Narrative Update Analysts have trimmed their implied price target for NovoCure to roughly US$20 from US$22, citing survey work that points to recovering procedure and CapEx trends into 2026, early signs of improvement in China, and ongoing sector rotation alongside potential ACA and Medicare changes that they believe warrant closer attention. Analyst Commentary Recent research points to a mixed setup for NovoCure, with valuation expectations recalibrated but longer term growth and execution themes still in focus.Narrativ-Update • Jan 21
NVCR: Recovering MedTech Demand And 2026 Setup Will Support Share Momentum
Analysts have nudged their fair value estimate for NovoCure slightly lower, trimming the target by under US$1 to reflect updated long-term assumptions and more conservative modeling, even as they factor in recovering end markets and 2026-focused sector views. Analyst Commentary Recent Street updates on NovoCure focus on slightly lower fair value targets and more conservative long-term models, even as some analysts highlight signs of healthier demand across medical technology and related capital spending into 2026.Narrativ-Update • Jan 06
NVCR: Recovering Medtech Procedures And CapEx Trends Will Support Upside Potential
Analysts have trimmed their price targets on NovoCure to a US$20 to US$23 range, citing more conservative long term assumptions. They also point to recovering end markets, sector rotation and healthier MedTech procedure and CapEx trends into 2026 as key context for the updated outlook.Narrativ-Update • Dec 14
NVCR: Long-Term Pipeline And Margin Outlook Will Support Upside Potential
Analysts have modestly raised their fair value estimate for NovoCure from $38.00 to about $41.25 per share, reflecting updated models that balance increased long term conservatism with slightly stronger profit margin expectations and a higher future earnings multiple. Analyst Commentary Analyst sentiment on NovoCure remains mixed, but recent updates show a constructive undertone even as some models become more conservative.Narrativ-Update • Nov 28
NVCR: Future Clinical Data Will Support Share Price Momentum Despite Cautious Outlook
Analysts have modestly lowered their price target for NovoCure from $25.00 to $23.00, citing increased long-term caution in their updated assessments. Analyst Commentary Following the revised price target, analysts offered balanced perspectives on NovoCure's outlook, weighing both positive catalysts and ongoing challenges for the company.Narrativ-Update • Nov 14
NVCR: Recent Clinical Progress Will Drive Upward Momentum Despite Raised Discount Rate
NovoCure Price Target Slightly Lowered Amid Updated Analyst Models Analysts have reduced their price target for NovoCure from $25.19 to $24.69 per share, citing more conservative long-term assumptions in their latest projections. Analyst Commentary Analyst perspectives on NovoCure's latest pricing and projections provide insight into key drivers and concerns affecting the company's valuation and outlook.Narrativ-Update • Oct 30
NVCR: Regulatory Wins And Clinical Milestones Will Drive Oncology Expansion
Narrative Update: NovoCure Analyst Price Target Adjusted Analysts have modestly reduced their price target for NovoCure from $27.19 to $25.19. They cite increased long-term conservatism in their latest models.Analyseartikel • Aug 21
Investors Give NovoCure Limited (NASDAQ:NVCR) Shares A 27% Hiding
NasdaqGS:NVCR 1 Year Share Price vs Fair Value Explore NovoCure's Fair Values from the Community and select yours...Analyseartikel • Jun 18
NovoCure Limited's (NASDAQ:NVCR) P/S Still Appears To Be Reasonable
With a median price-to-sales (or "P/S") ratio of close to 2.7x in the Medical Equipment industry in the United States...Analyseartikel • May 22
Is NovoCure (NASDAQ:NVCR) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Neues Narrativ • Mar 21
New FDA Approvals And Clinical Trials Will Expand Future Cancer Treatment Options
Recent FDA approvals and successful trials position Novocure for growth as it expands into multiple oncology indications, boosting its eligible patient population and revenue potential.Analyseartikel • Mar 01
Some Confidence Is Lacking In NovoCure Limited (NASDAQ:NVCR) As Shares Slide 25%
NovoCure Limited ( NASDAQ:NVCR ) shares have had a horrible month, losing 25% after a relatively good period...Seeking Alpha • Feb 28
NovoCure's Expansion Strategy Struggles To Translate Approvals Into Growth
Summary NovoCure's stock has risen 42% since my October recommendation, but revenue diversification outside of glioblastoma (GBM) remains a concern. Despite FDA approvals, TTFields therapy faces adoption challenges due to marginal survival benefits and high costs, impacting market growth. NovoCure's financial health shows sufficient liquidity short-term, but profit margins will compress and S&M costs will rise in 2025. I maintain a "sell" rating due to the maturing GBM market, slow adoption of new indications, and expected financial pressures. Read the full article on Seeking AlphaAnalyseartikel • Feb 12
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analyseartikel • Dec 03
NovoCure Limited (NASDAQ:NVCR) Looks Just Right With A 84% Price Jump
The NovoCure Limited ( NASDAQ:NVCR ) share price has done very well over the last month, posting an excellent gain of...Seeking Alpha • Dec 02
Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields
Summary Positive results achieved from phase 3 PANOVA-3 study using TTFields + Gemcitabine + Nab-paclitaxel to treat unresectable, locally advanced 1st-line pancreatic cancer patients. Multiple regulatory submissions, of TTFields therapy combination targeting locally advanced 1st-line pancreatic cancer patients, expected throughout 2025. Data from phase 2 PANOVA-4 trial, using TTFields + TECENTRIQ + Gemcitabine + Nab-paclitaxel to treat 1st-line metastatic pancreatic cancer patients, expected in 2026. Data from phase 3 TRIDENT study, using TTFields + radiation therapy + temozolomide to treat newly diagnosed patients, expected in 2026. Read the full article on Seeking AlphaAnalyseartikel • Nov 01
Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report
NovoCure Limited ( NASDAQ:NVCR ) just released its latest quarterly results and things are looking bullish. Revenues...Analyseartikel • Oct 17
Is NovoCure (NASDAQ:NVCR) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • Oct 16
NovoCure: There Is Still More Upside
Summary On October 15th, NovoCure Limited received FDA approval of its lung cancer treatment, which resulted in positive price action. The lung cancer market will significantly increase NovoCure's scale, on top of a strong core business that has beat growth expectations. With downside risks limited to execution or FDA recall, and a price target of $35.10, I raise my rating from buy to strong buy. Read the full article on Seeking AlphaSeeking Alpha • Oct 09
NovoCure's Stock Stagnates Amid Lack Of Progress Beyond GBM
Summary NovoCure's TTFields showed mixed clinical results in NSCLC, with minor overall survival improvement, questioning its broader adoption beyond glioblastoma. Financially, NovoCure remains strong with significant cash reserves and a positive GBM revenue trend, despite an operating loss. Pending trial results in pancreatic cancer and regulatory decisions for NSCLC could significantly impact NovoCure's market potential and stock performance. Given the lack of substantial progress outside GBM, I maintain a cautious "sell" recommendation on NovoCure's stock. Read the full article on Seeking AlphaAnalyseartikel • Sep 12
Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects
With a median price-to-sales (or "P/S") ratio of close to 3.4x in the Medical Equipment industry in the United States...Seeking Alpha • Jul 26
NovoCure Limited: A Post Q2 Analysis
Summary Today, we take a look at NovoCure Limited, which develops and manufactures tumor treating fields devices for solid tumor cancers. The company has beat expectations for both its first and second quarter results in 2024 and is pushing to garner approval for additional indications. An analysis of NovoCure following its better than expected performance Q2 results Thursday follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • May 03
NovoCure Limited Q1 Earnings: Core Business Accelerating
Summary NovoCure's Q1 earnings exceeded expectations, with growing revenue and cost reductions. Market data suggests faster growth for specialty oncology treatments, providing tailwinds for NovoCure's business. The core business is strong, with accelerated revenue growth and pursuit of new treatments, leading to significant upside potential. Read the full article on Seeking AlphaAnalyseartikel • Apr 08
NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Mar 28
NovoCure: Sell The METIS-Inspired Rally
Summary NovoCure’s METIS trial met its primary endpoint but missed key secondary outcomes, casting doubt on TTFields' efficacy in NSCLC. Despite hitting the primary endpoint, TTFields’ role in NSCLC treatment is questionable without significant overall survival benefits. NovoCure's financial health shows a steady cash runway despite declining revenues and increasing net losses. Recommendation: Sell NovoCure stock due to underwhelming METIS data and financial deceleration, despite a 15% rally. Read the full article on Seeking AlphaAktionärsrenditen
| NVCR | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 7.3% | 1.8% | 1.2% |
| 1Y | -4.8% | -17.9% | 28.7% |
Rendite im Vergleich zur Industrie: NVCR übertraf die Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -17.9 erzielte.
Rendite vs. Markt: NVCR hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 28.7 erzielte.
Preisvolatilität
| NVCR volatility | |
|---|---|
| NVCR Average Weekly Movement | 11.1% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: NVCR hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: NVCRDie wöchentliche Volatilität (11%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2000 | 1,605 | Frank Leonard | www.novocure.com |
NovoCure Limited, ein Onkologieunternehmen, beschäftigt sich mit der Entwicklung, Herstellung und Vermarktung von Geräten zur Behandlung von Tumorfeldern (TTFields) für die Behandlung von soliden Tumoren in den Vereinigten Staaten, Deutschland, Frankreich, Japan, Greater China und international. Zu seinen TTFields-Geräten gehören Optune Gio, Optune Lua und Optune Pax. Das Unternehmen hat auch laufende klinische Studien zur Untersuchung von TTFields bei Hirnmetastasen, Magenkrebs, Glioblastom, Leberkrebs, nicht-kleinzelligem Lungenkrebs, Bauchspeicheldrüsenkrebs und Eierstockkrebs.
NovoCure Limited's Grundlagenzusammenfassung
| NVCR grundlegende Statistiken | |
|---|---|
| Marktanteil | US$2.08b |
| Gewinn(TTM) | -US$173.05m |
| Umsatz(TTM) | US$674.41m |
3.1x
Kurs-Umsatz-Verhältnis-12.2x
Kurs-Gewinn-Verhältnis Ist NVCR zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| NVCR Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$674.41m |
| Kosten der Einnahmen | US$165.58m |
| Bruttogewinn | US$508.84m |
| Sonstige Ausgaben | US$681.88m |
| Gewinn | -US$173.05m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -1.49 |
| Bruttomarge | 75.45% |
| Nettogewinnspanne | -25.66% |
| Schulden/Eigenkapital-Verhältnis | 59.1% |
Wie hat sich NVCR auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/26 22:34 |
| Aktienkurs zum Tagesende | 2026/05/26 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
NovoCure Limited wird von 13 Analysten beobachtet. 7 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Michael King | Citizens JMP Securities, LLC |
| Gregory Gilbert | Deutsche Bank |
| Vijay Kumar | Evercore ISI |